Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Cash from Operations (2020 - 2025)

Vivos Therapeutics' Cash from Operations history spans 6 years, with the latest figure at 3763000.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 3763000.0 for Q4 2025, down 29.76% from a year ago — trailing twelve months through Dec 2025 was 15263000.0 (down 20.18% YoY), and the annual figure for FY2025 was 15263000.0, down 20.18%.
  • Cash from Operations for Q4 2025 was 3763000.0 at Vivos Therapeutics, up from 4200000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 2500000.0 in Q1 2024 to a low of 6100000.0 in Q1 2022.
  • The 5-year median for Cash from Operations is 3709000.0 (2021), against an average of 3759900.0.
  • The sharpest move saw Cash from Operations tumbled 792.63% in 2021, then surged 52.51% in 2023.
  • Year by year, Cash from Operations stood at 4122000.0 in 2021, then grew by 27.22% to 3000000.0 in 2022, then grew by 10.0% to 2700000.0 in 2023, then fell by 7.41% to 2900000.0 in 2024, then decreased by 29.76% to 3763000.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 3763000.0, 4200000.0, and 3504000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.